Clinical Trial Update: Phase II Exploratory Study of Sequential Triple Therapy (Temozolomide/Anlotinib/Bemarituzumab) in Combination With Concurrent Radiotherapy With Temozolomide and Anlotinib for the Maintenance Treatment of Diffuse Midline Gliomas in Children

View source ↗

Summary

A Phase II exploratory trial evaluating sequential triple therapy with temozolomide, anlotinib, and bemarituzumab plus concurrent radiotherapy for maintenance t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Midline Glioma

Drugs mentioned

• Anlotinib (anlotinib)
• Bemarituzumab (bemarituzumab)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Maintenance Treatment of Diffuse Midline Gliomas in Children | Status: NOT_YET_RECRUITING